fluvastatin

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Aging

Conditions

Aging, Inflammation

Trial Timeline

Oct 1, 2009 → Sep 1, 2014

NCT ID

NCT01045512

About fluvastatin

fluvastatin is a phase 2 stage product being developed by Novartis for Aging. The current trial status is terminated. This product is registered under clinical trial identifier NCT01045512. Target conditions include Aging, Inflammation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01045512	Phase 2	Terminated	Oct 1, 2009	Sep 1, 2014	Aging
NCT00136799	Phase 3	Completed	Jun 1, 2005	Apr 1, 2006	Mixed Dyslipidemia
NCT00125125	Approved	Completed	May 1, 2005	Dec 1, 2005	Dyslipidemia
NCT00138528	Approved	Completed	Oct 1, 2004	Feb 1, 2006	Metabolic Syndrome
NCT00171262	Approved	Completed	Aug 1, 2004	Jun 1, 2007	Dyslipidemia
NCT00171275	Approved	Completed	Nov 1, 2003	—	Coronary Disease
NCT00176410	Phase 2	UNKNOWN	Jan 1, 2003	Dec 1, 2009	Aortic Valve Stenosis
NCT00171236	Phase 3	Completed	Oct 1, 2001	Mar 1, 2005	Heterozygous Familial Hypercholesterolemia
NCT00565474	Approved	Completed	Sep 1, 2001	—	Graft Vasculopathy

Competing Products

20 competing products in Aging

See all competitors

Product	Company	Stage	Hype Score
HRS-9231 + Gadobutrol	Jiangsu Hengrui Medicine	Phase 2	52
HRS-1738 Injection	Jiangsu Hengrui Medicine	Phase 1/2	41
Ranolazine + Placebo to match ranolazine	Gilead Sciences	Approved	84
CP-424,391	Pfizer	Phase 2	51
Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 + Nivolumab Injection [Opdivo]	Bristol Myers Squibb	Phase 1	32
injectable poly-L-lactic acid	Sanofi	Approved	84
Gadobutrol (Gadavist/Gadovist, BAY86-4875)	Bayer	Pre-clinical	20
Gadobutrol (Gadovist, BAY86-4875) + Gadopentetate Dimeglumine (Magnevist, BAY86-4882)	Bayer	Phase 3	74
Iopromide (Ultravist, BAY86-4877)	Bayer	Pre-clinical	20
Gadoquatrane (BAY1747846)	Bayer	Phase 3	74
BAY86-4367 + BAY86-4367	Bayer	Phase 1	30
GBCAs	Bayer	Pre-clinical	20
Gadobutrol (Gadovist, BAY86-4875)	Bayer	Phase 3	74
BAY1747846	Bayer	Phase 1	30
Gadoterate (Dotarem/Clariscan) + Gadobutrol (Gadavist/Gadovist, BAY86-4875)	Bayer	Approved	82
Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol	Bayer	Phase 3	74
Gadobutrol (Gadovist, BAY86-4875)	Bayer	Pre-clinical	20
F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102)	Bayer	Phase 1	30
Gadopentetate dimeglumine (Magnevist, BAY86-6661)	Bayer	Phase 3	74
Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol	Bayer	Phase 3	74

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved